Fig. 3.

Impact of the combined inhibitors treatment on extracellular vesicle (EV)-induced migration potential. J82 human bladder urothelial carcinoma cells were exposed to 150 µg/ml protein from J82 cell-derived EVs and treated with either 5 µM CD147 inhibitor AC-73 alone (A) or a combination of 2.5 µM AC-73 and tissue factor pathway inhibitor (TFPI, 300 ng/ml, B) for 16 h. Relative migration was quantified via a Transwell assay utilizing 6–8 images of cells that traversed the microporous membrane per experiment